The expected value from a BioNTech and Matinas deal is off-the-charts bananas
Matinas appears to be on the verge of signing a deal with BioNTech
Instead of a licensing agreement, BioNTech should just buy out Matinas
Gilead Stock Drops as Remdesivir Sales Go Through the Roof and Management Promises Stock Buybacks
Market Thoughts - 01-10-21
Market Cap Spread Between Gilead and Roche Continues to Widen
Gilead is the Next Celgene - Similarities Between the Celgene Buyout and Gilead
